The biotech IPO boom is becoming ‘historic’ as four more throw their hats in
Four more US biotechs filed to go public Friday as yet more companies clamber to get through a yawning IPO window and onto a market that’s signaled its willingness to reward nearly any new drugmaker.
The new entrants are led by ALX Oncology and the biological analytics biotech Berkeley Lights, each of whom filed to raise $100 million. The autoimmune company Pandion Therapeutics also filed for $75 million, and Kiromic Biopharma, a tiny immuno-oncology startup based in San Antonio, filed for $25 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
